Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Mol Cancer Ther ; 22(8): 903-912, 2023 08 01.
Article in English | MEDLINE | ID: mdl-37294945

ABSTRACT

CD3 bispecific T-cell engagers (TCE), comprised of a tumor-targeting domain linked to a CD3 binding domain, function by bridging target-positive tumors and CD3-expressing effector T cells enabling redirected T cell-mediated killing of tumor cells. Although the majority of CD3 bispecific molecules in clinical development incorporate tumor-targeting antibody-based binding domains, many tumor-associated antigens derive from intracellular proteins and are not accessible to targeting via antibody. Intracellular proteins processed into short peptide fragments and presented on the cell surface by MHC proteins are recognized by T-cell receptors (TCR) on the surface of T cells. Here we describe the generation and preclinical evaluation of ABBV-184, a novel TCR/anti-CD3 bispecific composed of a highly selective soluble TCR that binds a peptide derived from the oncogene survivin (BIRC5) bound to the class I MHC allele human leukocyte antigen (HLA)-A*02:01 expressed on tumor cells, linked to a specific binder to the CD3 receptor on T cells. ABBV-184 drives an optimal distance between T cell and target cell thereby enabling sensitive recognition of low-density peptide/MHC targets. Consistent with the expression profile of survivin across a broad range of both hematologic and solid tumors, treatment of acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC) cell lines with ABBV-184 results in T-cell activation, proliferation, and potent redirected cytotoxicity of HLA-A2-positive target cell lines, both in vitro and in vivo, including patient-derived AML samples. These results indicate that ABBV-184 is an attractive clinical candidate for the treatment of patients with AML and NSCLC.


Subject(s)
Antibodies, Bispecific , Carcinoma, Non-Small-Cell Lung , Hematologic Neoplasms , Leukemia, Myeloid, Acute , Lung Neoplasms , Humans , T-Lymphocytes , Carcinoma, Non-Small-Cell Lung/metabolism , Survivin/metabolism , Lung Neoplasms/metabolism , Receptors, Antigen, T-Cell , CD3 Complex , Leukemia, Myeloid, Acute/pathology , Hematologic Neoplasms/metabolism , Antibodies, Bispecific/pharmacology , Antibodies, Bispecific/therapeutic use
2.
Mol Immunol ; 68(2 Pt A): 203-12, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26320630

ABSTRACT

Bacterial lipopolysaccharide (LPS) activates the innate immune system by forming a complex with myeloid differentiation factor 2 (MD-2) and Toll-like receptor 4 (TLR4), which is present on antigen presenting cells. MD-2 plays an essential role in this activation of the innate immune system as a member of the ternary complex, TLR4:MD-2:LPS. With the goal of further understanding the molecular details of the interaction of MD-2 with LPS and TLR4, and possibly toward engineering dominant negative regulators of the MD-2 protein, here we subjected MD-2 to a mutational analysis using yeast display. The approach included generation of site-directed alanine mutants, and ligand-driven selections of MD-2 mutant libraries. Our findings showed that: (1) proline mutations in the F119-K132 loop that binds LPS were strongly selected for enhanced yeast surface stability, (2) there was a preference for positive-charged side chains (R/K) at residue 120 for LPS binding, and negative-charged side chains (D/E) for TLR4 binding, (3) aromatic residues were strongly preferred at F119 and F121 for LPS binding, and (4) an MD-2 mutant (T84N/D101A/S118A/S120D/K122P) exhibited increased binding to TLR4 but decreased binding to LPS. These studies revealed the impact of specific residues and regions of MD-2 on the binding of LPS and TLR4, and they provide a framework for further directed evolution of the MD-2 protein.


Subject(s)
Lipopolysaccharides/metabolism , Saccharomyces cerevisiae/genetics , Toll-Like Receptor 4/genetics , Amino Acid Sequence , Binding Sites , Gene Expression , Humans , Immunity, Innate , Lipopolysaccharides/chemistry , Lipopolysaccharides/immunology , Lymphocyte Antigen 96/chemistry , Lymphocyte Antigen 96/genetics , Lymphocyte Antigen 96/immunology , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Mutation , Peptide Library , Protein Binding , Protein Structure, Secondary , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Saccharomyces cerevisiae/metabolism , Static Electricity , Structure-Activity Relationship , Toll-Like Receptor 4/chemistry , Toll-Like Receptor 4/immunology
3.
PLoS One ; 10(8): e0135986, 2015.
Article in English | MEDLINE | ID: mdl-26305471

ABSTRACT

Staphylococcal and streptococcal exotoxins, also known as superantigens, mediate a range of diseases including toxic shock syndrome, and they exacerbate skin, pulmonary and systemic infections caused by these organisms. When present in food sources they can cause enteric effects commonly known as food poisoning. A rapid, sensitive assay for the toxins would enable testing of clinical samples and improve surveillance of food sources. Here we developed a bead-based, two-color flow cytometry assay using single protein domains of the beta chain of T cell receptors engineered for high-affinity for staphylococcal (SEA, SEB and TSST-1) and streptococcal (SpeA and SpeC) toxins. Site-directed biotinylated forms of these high-affinity agents were used together with commercial, polyclonal, anti-toxin reagents to enable specific and sensitive detection with SD50 values of 400 pg/ml (SEA), 3 pg/ml (SEB), 25 pg/ml (TSST-1), 6 ng/ml (SpeA), and 100 pg/ml (SpeC). These sensitivities were in the range of 4- to 80-fold higher than achieved with standard ELISAs using the same reagents. A multiplex format of the assay showed reduced sensitivity due to higher noise associated with the use of multiple polyclonal agents, but the sensitivities were still well within the range necessary for detection in food sources or for rapid detection of toxins in culture supernatants. For example, the assay specifically detected toxins in supernatants derived from cultures of Staphylococcus aureus. Thus, these reagents can be used for simultaneous detection of the toxins in food sources or culture supernatants of potential pathogenic strains of Staphylococcus aureus and Streptococcus pyogenes.


Subject(s)
Bacterial Toxins/analysis , Biological Assay/methods , Exotoxins/analysis , Staphylococcus aureus/chemistry , Streptococcus pyogenes/chemistry , Biotinylation , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Microspheres , Receptors, Antigen, T-Cell, alpha-beta/chemistry
4.
Cancer Immunol Immunother ; 63(11): 1163-76, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25082071

ABSTRACT

Adoptive transfer of genetically modified T cells to treat cancer has shown promise in several clinical trials. Two main strategies have been applied to redirect T cells against cancer: (1) introduction of a full-length T cell receptor (TCR) specific for a tumor-associated peptide-MHC, or (2) introduction of a chimeric antigen receptor, including an antibody fragment specific for a tumor cell surface antigen, linked intracellularly to T cell signaling domains. Each strategy has advantages and disadvantages for clinical applications. Here, we present data on the in vitro and in vivo effectiveness of a single-chain signaling receptor incorporating a TCR variable fragment as the targeting element (referred to as TCR-SCS). This receptor contained a single-chain TCR (Vα-linker-Vß) from a high-affinity TCR called m33, linked to the intracellular signaling domains of CD28 and CD3ζ. This format avoided mispairing with endogenous TCR chains and mediated specific T cell activity when expressed in either CD4 or CD8 T cells. TCR-SCS-transduced CD8-negative cells showed an intriguing sensitivity, compared to full-length TCRs, to higher densities of less stable pepMHC targets. T cells that expressed this peptide-specific receptor persisted in vivo, and exhibited polyfunctional responses. Growth of metastatic antigen-positive tumors was significantly inhibited by T cells that expressed this receptor, and tumor cells that escaped were antigen-loss variants. TCR-SCS receptors represent an alternative targeting receptor strategy that combines the advantages of single-chain expression, avoidance of TCR chain mispairing, and targeting of intracellular antigens presented in complex with MHC proteins.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Neoplasms/immunology , Receptors, Antigen, T-Cell, alpha-beta/immunology , Adoptive Transfer , Animals , CD28 Antigens/metabolism , CD3 Complex/metabolism , Cytokines/metabolism , Humans , Major Histocompatibility Complex , Melanoma, Experimental , Mice , Mice, Inbred C57BL , Neoplasm Metastasis , Neoplasm Transplantation , Receptors, Antigen, T-Cell, alpha-beta/genetics , Signal Transduction/immunology , Transduction, Genetic
5.
Cancer Immunol Immunother ; 62(2): 359-69, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22926060

ABSTRACT

Clinical studies with immunotherapies for cancer, including adoptive cell transfers of T cells, have shown promising results. It is now widely believed that recruitment of CD4(+) helper T cells to the tumor would be favorable, as CD4(+) cells play a pivotal role in cytokine secretion as well as promoting the survival, proliferation, and effector functions of tumor-specific CD8(+) cytotoxic T lymphocytes. Genetically engineered high-affinity T-cell receptors (TCRs) can be introduced into CD4(+) helper T cells to redirect them to recognize MHC-class I-restricted antigens, but it is not clear what affinity of the TCR will be optimal in this approach. Here, we show that CD4(+) T cells expressing a high-affinity TCR (nanomolar K (d) value) against a class I tumor antigen mediated more effective tumor treatment than the wild-type affinity TCR (micromolar K (d) value). High-affinity TCRs in CD4(+) cells resulted in enhanced survival and long-term persistence of effector memory T cells in a melanoma tumor model. The results suggest that TCRs with nanomolar affinity could be advantageous for tumor targeting when expressed in CD4(+) T cells.


Subject(s)
Antigens, Neoplasm/immunology , CD4-Positive T-Lymphocytes/immunology , Genes, MHC Class I/immunology , Melanoma, Experimental/immunology , Receptors, Antigen, T-Cell/immunology , Skin Neoplasms/immunology , Adoptive Transfer , Animals , Antineoplastic Agents/therapeutic use , CD4-Positive T-Lymphocytes/chemistry , CD8-Positive T-Lymphocytes/immunology , Cell Line, Tumor , Cell Survival/immunology , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Interferon-gamma/therapeutic use , Mice , Mice, Inbred C57BL , Receptors, Antigen, T-Cell/biosynthesis , Receptors, Antigen, T-Cell/chemistry , Receptors, Antigen, T-Cell/genetics
6.
Biotechnol Prog ; 28(6): 1588-97, 2012.
Article in English | MEDLINE | ID: mdl-22961781

ABSTRACT

To avoid high systemic doses, strategies involving antigen-specific delivery of cytokine via linked antibodies or antibody fragments have been used. Targeting cancer-associated peptides presented by major histocompatibility complex (MHC) molecules (pepMHC) increases the number of potential target antigens and takes advantage of cross-presentation on tumor stroma and in draining lymph nodes. Here, we use a soluble, high-affinity single-chain T cell receptor Vα-Vß (scTv), to deliver cytokines to intracellular tumor-associated antigens presented as pepMHC. As typical wild-type T cell receptors (TCRs) exhibit low affinity (K(d) = 1-100 µM or more), we used an engineered TCR, m33, that binds its antigenic peptide SIYRYYGL (SIY) bound to the murine class I major histocompatability complex protein H2-K(b) (SIY/K(b) ) with nanomolar affinity (K(d) = 30 nM). We generated constructs consisting of m33 scTv fused to murine interleukin 2 (IL-2), interleukin 15 (IL-15), or IL-15/IL-15Rα (IL-15 linked to IL-15Rα sushi domain, called "superfusion"). The fusions were purified with good yields and bound specifically to SIY/K(b) with high affinity. Proper cytokine folding and binding were confirmed, and the fusions were capable of stimulating proliferation of cytokine-dependent cells, both when added directly and when presented in trans, bound to cells with the target pepMHC. The m33 superfusion was particularly potent and stable and represents a promising design for targeted antitumor immunomodulation.


Subject(s)
Interleukin-15 Receptor alpha Subunit/chemistry , Interleukin-15/chemistry , Protein Engineering/methods , Receptors, Antigen, T-Cell/chemistry , Recombinant Fusion Proteins/chemistry , Animals , Cell Line, Tumor , Cell Proliferation , Drug Delivery Systems , Humans , Interleukin-15/agonists , Interleukin-15/genetics , Interleukin-15/metabolism , Interleukin-15 Receptor alpha Subunit/agonists , Interleukin-15 Receptor alpha Subunit/genetics , Interleukin-15 Receptor alpha Subunit/metabolism , Mice , Oligopeptides/chemistry , Oligopeptides/metabolism , Protein Binding , Rats , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/metabolism , Recombinant Fusion Proteins/agonists , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism
7.
Mol Ther ; 20(3): 652-60, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22233579

ABSTRACT

Most T cells have T cell receptors (TCR) of micromolar affinity for peptide-major histocompatibility complex (MHC) ligands, but genetic engineering can generate TCRs of nanomolar affinity. The affinity of the TCR used, m33, for its cognate non-self peptide-MHC-I complex (SIYRYYGL-K(b)) is 1,000-fold higher than of the wild-type TCR 2C. The affinity of m33 for the self-peptide dEV-8 on K(b) is only twofold higher. Mouse CD8(+) T cells transduced with an m33-encoding retrovirus showed binding of SIY-K(b) and potent function in vitro, but in vivo these T cells disappeared within hours after transfer into syngeneic hosts without causing graft-versus-host disease (GVHD). Accordingly, in cases where such CD8-dependent self-reactivity might occur in human adoptive T cell therapies, our results show that a peripheral T-cell deletion mechanism could operate to avoid reactions with the host. In contrast to CD8(+) T cells, we show that CD4(+) T cells expressing m33 survived for months in vivo. Furthermore, the m33-transduced CD4(+) T cells were able to mediate antigen-specific rejection of 6-day-old tumors. Together, we show that CD8(+) T cell expressing a MHC class I-restricted high-affinity TCR were rapidly deleted whereas CD4(+) T cells expressing the same TCR survived and provided function while being directed against a class I-restricted antigen.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Histocompatibility Antigens Class I/immunology , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/immunology , Amino Acid Sequence , Animals , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Cell Line , Cell Survival/immunology , Gene Expression , Genetic Vectors/genetics , Immunotherapy, Adoptive , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/therapy , Oligopeptides/immunology , Peptides/chemistry , Peptides/immunology , Retroviridae/genetics , Transduction, Genetic
8.
Methods Enzymol ; 503: 189-222, 2012.
Article in English | MEDLINE | ID: mdl-22230570

ABSTRACT

T lymphocytes express on their surface a heterodimeric αß receptor, called the T cell receptor (TCR), which recognizes foreign antigens. Unlike antibodies, the recognition requires both an antigenic peptide epitope and a protein encoded by the major histocompatibility complex (MHC). In contrast to conventional antibody-directed target antigens, antigens recognized by the TCR can include the entire array of potential intracellular proteins, which are processed and delivered to the cell surface as a peptide/MHC complex. In the past 10 years, there have been significant efforts to engineer TCRs in various formats, which would allow improved recognition and destruction of virus-infected cells or cancer. The proposed therapeutic approaches involve either the use of engineered, high-affinity TCRs in soluble forms, analogous to antibody-directed therapies, or the use of engineered TCRs whose genes are reintroduced into autologous T cells and transferred back into patients (T cell adoptive therapies). This chapter describes three methods associated with the engineering of TCRs for these therapeutic purposes: (1) use of a yeast display system to engineer higher affinity single-chain VαVß TCRs, called scTv; (2) use of a T cell display system to engineer higher affinity full-length TCRs; and (3) expression, purification, and characterization of soluble TCRs in an Escherichia coli system.


Subject(s)
Protein Engineering/methods , Receptors, Antigen, T-Cell/chemistry , Single-Chain Antibodies/chemistry , T-Lymphocytes/chemistry , Cloning, Molecular , Complementarity Determining Regions/chemistry , Complementarity Determining Regions/genetics , Enzyme-Linked Immunosorbent Assay , Epitopes/chemistry , Escherichia coli/chemistry , Flow Cytometry , Humans , Major Histocompatibility Complex , Peptide Library , Protein Refolding , Protein Stability , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/isolation & purification , Receptors, Antigen, T-Cell/therapeutic use , Receptors, Cell Surface , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Single-Chain Antibodies/genetics , Single-Chain Antibodies/isolation & purification , Single-Chain Antibodies/therapeutic use , Solubility , Transgenes , Yeasts/chemistry
9.
J Immunol ; 187(12): 6281-90, 2011 Dec 15.
Article in English | MEDLINE | ID: mdl-22102724

ABSTRACT

The binding of oligomeric peptide-MHC (pMHC) complexes to cell surface TCR can be considered to approximate TCR-pMHC interactions at cell-cell interfaces. In this study, we analyzed the equilibrium binding of streptavidin-based pMHC oligomers (tetramers) and their dissociation kinetics from CD8(pos) T cells from 2C-TCR transgenic mice and from T cell hybridomas that expressed the 2C TCR or a high-affinity mutant (m33) of this TCR. Our results show that the tetramers did not come close to saturating cell-surface TCR (binding only 10-30% of cell-surface receptors), as is generally assumed in deriving affinity values (K(D)), in part because of dissociative losses from tetramer-stained cells. Guided by a kinetic model, the oligomer dissociation rate and equilibrium constants were seen to depend not only on monovalent association and dissociation rates (k(off) and k(on)), but also on a multivalent association rate (µ) and TCR cell-surface density. Our results suggest that dissociation rates could account for the recently described surprisingly high frequency of tetramer-negative, functionally competent T cells in some T cell responses.


Subject(s)
Major Histocompatibility Complex/immunology , Membrane Proteins/metabolism , Models, Immunological , Multiprotein Complexes/metabolism , Peptides/metabolism , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Streptavidin/metabolism , Animals , Hybridomas , Major Histocompatibility Complex/genetics , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Multiprotein Complexes/genetics , Protein Binding/immunology , Receptors, Antigen, T-Cell, alpha-beta/genetics , Single-Chain Antibodies/metabolism
10.
J Immunol ; 186(9): 5193-200, 2011 May 01.
Article in English | MEDLINE | ID: mdl-21451107

ABSTRACT

Nonstimulatory or endogenous peptide-MHC (pepMHC) presented on the surfaces of APCs, either alone or alongside agonist pepMHC, plays various roles in T cell selection and activation. To examine these properties in more detail, we explored several model systems of TCR and pepMHC ligands with sufficient affinity to be activated in the absence of CD8. The TCRs had a range of affinities for agonist and nonstimulatory ligands and were restricted by MHC class I alleles with different properties. We observed CD8-independent antagonism from TCR-pepMHC interactions with very low affinities (e.g., K(D) = 300 µM). In addition, endogenous peptide-L(d) complexes on APCs antagonized activation of coreceptor (CD8)-negative 2C T cells even by the strong agonist QL9-L(d). In contrast, TCRs m33 and 3D-PYY, restricted by K(b) and D(b), respectively, did not show signs of antagonism by endogenous pepMHC in the absence of CD8. This did not appear to be an inherent difference in the ability of the TCRs to be antagonized, as altered peptide ligands could antagonize each TCR. In the presence of CD8, endogenous pepMHC ligands acted in some cases as coagonists. These results show that endogenous pepMHC molecules exhibit complex behavior in T cells, leading to either reduced activity (e.g., in cases of low coreceptor levels) or enhanced activity (e.g., in presence of coreceptor). The behavior may be influenced by the ability of different TCRs to recognize endogenous pepMHC but also perhaps by the inherent properties of the presenting MHC allele.


Subject(s)
Antigen Presentation/immunology , CD8 Antigens/immunology , Histocompatibility Antigens Class I/immunology , Lymphocyte Activation/immunology , T-Lymphocytes/immunology , Animals , Autoantigens/immunology , Cell Separation , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Mice , Peptides/immunology , Receptors, Antigen, T-Cell/immunology
11.
Protein Eng Des Sel ; 24(4): 361-72, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21159619

ABSTRACT

Single-chain antibody fragments (scFv), consisting of two linked variable regions (V(H) and V(L)), are a versatile format for engineering and as potential antigen-specific therapeutics. Although the analogous format for T cell receptors (TCRs), consisting of two linked V regions (Vα and Vß; referred to here as scTv), could provide similar opportunities, all wild-type scTv proteins examined to date are unstable. This obstacle has prevented scTv fragments from being widely used for engineering or therapeutics. To further explore whether some stable human scTv fragments could be expressed, we used a yeast system in which display of properly folded domains correlates with ability to express the folded scTv in soluble form. We discovered that, unexpectedly, scTv fragments that contained the human Vα2 region (IMGT: TRAV12 family) were displayed and properly associated with different Vß regions. Furthermore, a single polymorphic residue (Ser(α49)) in the framework region conferred additional thermal stability. These stabilized Vα2-containing scTv fragments could be expressed at high levels in Escherichia coli, and used to stain target cells that expressed the specific pep-HLA-A2 complexes. Thus, the scTv fragments can serve as a platform for engineering TCRs with diverse specificities, and possibly for therapeutic or diagnostic applications.


Subject(s)
Protein Engineering/methods , Receptors, Antigen, T-Cell, alpha-beta/biosynthesis , Receptors, Antigen, T-Cell, alpha-beta/immunology , Single-Chain Antibodies/biosynthesis , Single-Chain Antibodies/immunology , Cloning, Molecular , Escherichia coli/genetics , Escherichia coli/metabolism , HLA-A2 Antigen/immunology , Humans , Peptides/immunology , Protein Conformation , Protein Folding , Receptors, Antigen, T-Cell, alpha-beta/chemistry , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Single-Chain Antibodies/chemistry
12.
J Immunol ; 183(12): 7639-43, 2009 Dec 15.
Article in English | MEDLINE | ID: mdl-19923452

ABSTRACT

It has been proposed that MHC restriction during thymocyte selection is controlled by coreceptor (CD4 or CD8) sequestration of the signaling molecule Lck. We explored this model as a mechanism for preventing peripheral T cell activation due to non-MHC ligand cross-reactivities of TCRs. TCRs that have a range of affinities for a class I MHC ligand were transduced into a T cell hybridoma in the absence or presence of coreceptors. High and intermediate affinity TCRs (K(D) = 17 and 540 nM) did not require CD8 for T cell activity, but CD4 acted as a potent inhibitor of the intermediate affinity TCR. These and other findings support the view that even high-affinity TCR:ligand interactions can be influenced by coreceptor sequestration of Lck. Thus, CD4 and CD8 act as "coreceptor inhibitors" to maintain appropriate TCR-mediated MHC restriction in peripheral T cell activity.


Subject(s)
CD4 Antigens/physiology , CD8 Antigens/physiology , Immunosuppressive Agents , Lymphocyte Activation/immunology , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , Animals , Antigen Presentation , CD4 Antigens/metabolism , CD8 Antigens/metabolism , Cells, Cultured , H-2 Antigens/immunology , H-2 Antigens/metabolism , Hybridomas , Immune Tolerance , Immunosuppressive Agents/metabolism , Ligands , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/immunology , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism , Mice , Mice, Inbred C57BL , Protein Binding/immunology , Receptors, Antigen, T-Cell/antagonists & inhibitors , Receptors, Antigen, T-Cell/biosynthesis , Receptors, Antigen, T-Cell/metabolism , T-Lymphocyte Subsets/enzymology
13.
J Immunol ; 183(2): 1166-78, 2009 Jul 15.
Article in English | MEDLINE | ID: mdl-19553539

ABSTRACT

TCR interactions with cognate peptide-MHC (pepMHC) ligands are generally low affinity. This feature, together with the requirement for CD8/CD4 participation, has made it difficult to dissect relationships between TCR-binding parameters and T cell activation. Interpretations are further complicated when comparing different pepMHC, because these can vary greatly in stability. To examine the relationships between TCR-binding properties and T cell responses, in this study we characterized the interactions and activities mediated by a panel of TCRs that differed widely in their binding to the same pepMHC. Monovalent binding of soluble TCR was characterized by surface plasmon resonance, and T cell hybridomas that expressed these TCR, with or without CD8 coexpression, were tested for their binding of monomeric and oligomeric forms of the pepMHC and for subsequent responses (IL-2 release). The binding threshold for eliciting this response in the absence of CD8 (K(D) = 600 nM) exhibited a relatively sharp cutoff between full activity and no activity, consistent with a switchlike response to pepMHC on APCs. However, when the pepMHC was immobilized (plate bound), T cells with the lowest affinity TCRs (e.g., K(D) = 30 microM) responded, even in the absence of CD8, indicating that these TCR are signaling competent. Surprisingly, even cells that expressed high-affinity (K(D) = 16 nM) TCRs along with CD8 were unresponsive to oligomers in solution. The findings suggest that to drive downstream T cell responses, pepMHC must be presented in a form that supports formation of appropriate supramolecular clusters.


Subject(s)
Antigen Presentation , Peptides/chemistry , Peptides/immunology , Receptors, Antigen, T-Cell/immunology , T-Lymphocytes/immunology , Animals , Antigen-Presenting Cells , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Hybridomas , Ligands , Mice , Peptides/chemical synthesis , Protein Binding/immunology , Surface Plasmon Resonance
14.
Immunology ; 126(2): 165-76, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19125887

ABSTRACT

The interaction between the T-cell receptor (TCR) and its peptide-major histocompatibility complex (pepMHC) ligand plays a critical role in determining the activity and specificity of the T cell. The binding properties associated with these interactions have now been studied in many systems, providing a framework for a mechanistic understanding of the initial events that govern T-cell function. There have been various other reviews that have described the structural and biochemical features of TCR : pepMHC interactions. Here we provide an overview of four areas that directly impact our understanding of T-cell function, as viewed from the perspective of the TCR : pepMHC interaction: (1) relationships between T-cell activity and TCR : pepMHC binding parameters, (2) TCR affinity, avidity and clustering, (3) influence of coreceptors on pepMHC binding by TCRs and T-cell activity, and (4) impact of TCR binding affinity on antigenic peptide specificity.


Subject(s)
Receptors, Antigen, T-Cell/metabolism , T-Lymphocyte Subsets/immunology , Epitopes, T-Lymphocyte/immunology , Humans , Ligands , Lymphocyte Activation/immunology , Major Histocompatibility Complex/immunology , Peptides/immunology , Protein Binding/immunology
15.
J Immunol Methods ; 339(2): 175-84, 2008 Dec 31.
Article in English | MEDLINE | ID: mdl-18854190

ABSTRACT

The T cell receptor (TCR) determines the cellular response to antigens, which are presented on the surface of target cells in the form of a peptide bound to a product of the major histocompatibility complex (pepMHC). The response of the T cell depends on the affinity of the TCR for the pepMHC, yet many TCRs have been shown to be of low affinity, and some naturally occurring T cell responses are poor due to low affinities. Accordingly, engineering the TCR for increased affinity for pepMHC, particularly tumor-associated antigens, has become an increasingly desirable goal, especially with the advent of adoptive T cell therapies. For largely technical reasons, to date there have been only a handful of TCRs engineered in vitro for higher affinity using well established methods of protein engineering. Here we report the use of a T cell display system, using a retroviral vector, for generating a high-affinity TCR from the mouse T cell clone 2C. The method relies on the display of the TCR, in its normal, signaling competent state, as a CD3 complex on the T cell surface. A library in the CDR3alpha of the 2C TCR was generated in the MSCV retroviral vector and transduced into a TCR-negative hybridoma. Selection of a high-affinity, CD8-independent TCR was accomplished after only two rounds of flow cytometric sorting using the pepMHC SIYRYYGL/Kb (SIY/Kb). The selected TCR contained a sequence motif in the CDR3alpha with characteristics of several other TCRs previously selected by yeast display. In addition, it was possible to directly use the selected T cell hybridoma in functional assays without the need for sub-cloning, revealing that the selected TCR was capable of mediating CD8-independent activity. The method may be useful in the direct isolation and characterization of TCRs that could be used in therapies with adoptive transferred T cells.


Subject(s)
Complementarity Determining Regions/genetics , Complementarity Determining Regions/immunology , Oligopeptides/immunology , Protein Engineering/methods , T-Lymphocytes/immunology , Animals , CD8 Antigens/genetics , CD8 Antigens/immunology , Genetic Vectors , Hybridomas/immunology , Mice , Retroviridae , T-Lymphocytes/transplantation , Transduction, Genetic/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...